Vendor review
Inno Peptides reviews
Inno Peptides reviews from 58 independent lab tests (Retatrutide, Tirzepatide and GHK-Cu): grade A, purity and fill accuracy. Is Inno Peptides legit? See what its vials showed.
What the lab tests show
58 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Oct 12, 2026 | Retatrutide | 99.6 % | 30.1 mg of 30 mg (0 %) | Pass | View |
| Oct 8, 2026 | Cagrilintide | 99.9 % | 4.78 mg of 5 mg (-4 %) | Pass | View |
| Oct 8, 2026 | Cagrilintide | 99.9 % | 4.76 mg of 5 mg (-5 %) | Pass | View |
| Oct 6, 2026 | Tirzepatide | 99.9 % | 43.4 mg of 40 mg (9 %) | Pass | View |
| Oct 6, 2026 | Retatrutide | 99.9 % | 15.9 mg of 15 mg (6 %) | Pass | View |
| Sep 25, 2026 | Tirzepatide | 99.9 % | 56.7 mg of 60 mg (-5 %) | Pass | View |
| Sep 25, 2026 | BPC-157 | 99.9 % | 11.2 mg of 10 mg (12 %) | Pass | View |
| Sep 23, 2026 | Retatrutide | 99.9 % | 17.7 mg of 20 mg (-12 %) | Pass | View |
| Sep 21, 2026 | Tesamorelin | 97.55 % | 5.76 mg of 10 mg (-42 %) | Pass | View |
| Sep 18, 2026 | BPC-157 | 99.99 % | 9.63 mg of 10 mg (-4 %) | Pass | View |
| Sep 18, 2026 | Retatrutide | 91.8 % | 27.9 mg of 30 mg (-7 %) | Pass | View |
| Sep 17, 2026 | Retatrutide | 98 % | 11 mg of 10 mg (10 %) | Pass | View |
| Sep 16, 2026 | Retatrutide | 95.99 % | 23.4178 mg of 20 mg (17 %) | Pass | View |
| Sep 16, 2026 | Retatrutide | 96.56 % | 12.1499 mg of 10 mg (21 %) | Pass | View |
| Sep 16, 2026 | Tirzepatide | 99.9 % | 65.5 mg of 60 mg (9 %) | Pass | View |
| Sep 4, 2026 | MOTS-c | 99.6 % | 10.1 mg of 10 mg (1 %) | Pass | View |
| Aug 27, 2026 | Tirzepatide | 95.72 % | 69.33 mg of 60 mg (16 %) | Pass | View |
| Aug 13, 2026 | Retatrutide | 99.9 % | 8.68 mg of 10 mg (-13 %) | Pass | View |
| Aug 13, 2026 | BPC-157 | 99.9 % | 8.17 mg of 10 mg (-18 %) | Pass | View |
| Aug 12, 2026 | Retatrutide | 99.9 % | 29.9 mg of 30 mg (0 %) | Pass | View |
| Aug 12, 2026 | MOTS-c | 98.3 % | 9.09 mg of 10 mg (-9 %) | Pass | View |
| Aug 9, 2026 | Retatrutide | 99.8 % | 10.1 mg of 10 mg (1 %) | Pass | View |
| Aug 9, 2026 | GHK-Cu | 99.7 % | 52.2 mg of 50 mg (4 %) | Pass | View |
| Aug 9, 2026 | Retatrutide | 99.8 % | 11.1 mg of 10 mg (11 %) | Pass | View |
| Aug 4, 2026 | Retatrutide | 99.9 % | 9.9 mg of 10 mg (-1 %) | Pass | View |
| Aug 4, 2026 | Retatrutide | 99.9 % | 8.63 mg of 10 mg (-14 %) | Pass | View |
| Aug 3, 2026 | Retatrutide | 99.9 % | 54.5 mg of 60 mg (-9 %) | Pass | View |
| Aug 3, 2026 | Tirzepatide | 99.1 % | 52.3 mg of 60 mg (-13 %) | Pass | View |
| Aug 3, 2026 | GHK-Cu | 99.9 % | 107 mg of 100 mg (7 %) | Pass | View |
| Aug 3, 2026 | BPC-157 | 99.9 % | 8.71 mg of 10 mg (-13 %) | Pass | View |
| Aug 3, 2026 | Tesamorelin | 99.9 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Jul 17, 2026 | Retatrutide | 99.9 % | 19.5 mg of 20 mg (-3 %) | Pass | View |
| Jul 15, 2026 | Retatrutide | 99.8 % | 21.5 mg of 20 mg (8 %) | Pass | View |
| Jul 13, 2026 | Tirzepatide | 99.8 % | 39.8 mg of 40 mg (-1 %) | Pass | View |
| Jul 13, 2026 | MOTS-c | 98.3 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| Jun 26, 2026 | Retatrutide | 99.6 % | 9.4 mg of 10 mg (-6 %) | Pass | View |
| Jun 26, 2026 | Retatrutide | 10 mg | View | ||
| Jun 26, 2026 | Retatrutide | 99.8 % | 9.9 mg of 10 mg (-1 %) | Pass | View |
| Jun 26, 2026 | BPC-157 | 99.6 % | 11 mg of 10 mg (10 %) | Pass | View |
| Jun 16, 2026 | Tirzepatide | 99.9 % | 25.3 mg of 30 mg (-16 %) | Pass | View |
| Jun 5, 2026 | Retatrutide | 99.9 % | 27.7 mg of 30 mg (-8 %) | Pass | View |
| May 13, 2026 | GHK-Cu | 99.6 % | 45.6 mg of 50 mg (-9 %) | Pass | View |
| May 13, 2026 | MOTS-c | 99.9 % | 44.1 mg of 40 mg (10 %) | Pass | View |
| May 11, 2026 | Retatrutide | 99.9 % | 17.3 mg of 20 mg (-14 %) | Pass | View |
| May 5, 2026 | Retatrutide | 99.9 % | 9.56 mg of 10 mg (-4 %) | Pass | View |
| May 5, 2026 | Tirzepatide | 99.9 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| May 5, 2026 | GHK-Cu | 99.9 % | 38.8 mg of 50 mg (-22 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 18.1 mg of 20 mg (-10 %) | Pass | View |
| Apr 28, 2026 | Tirzepatide | 99.9 % | 35.9 mg of 30 mg (20 %) | Pass | View |
| Mar 19, 2026 | Retatrutide | 99.9 % | 26.9 mg of 30 mg (-10 %) | Pass | View |
| Mar 17, 2026 | Tirzepatide | 99.8 % | 34.7 mg of 30 mg (16 %) | Pass | View |
| Mar 10, 2026 | GHK-Cu | 99.86 % | 85.7 mg of 100 mg (-14 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 11.6 mg of 10 mg (16 %) | Pass | View |
| Mar 4, 2026 | Retatrutide | 99.9 % | 22.3 mg of 20 mg (12 %) | Pass | View |
| Mar 4, 2026 | GHK-Cu | 99.7 % | 54 mg of 50 mg (8 %) | Pass | View |
| Mar 2, 2026 | Retatrutide | 99.9 % | 8.45 mg of 10 mg (-16 %) | Pass | View |
| Mar 2, 2026 | Tirzepatide | 99.9 % | 28.2 mg of 30 mg (-6 %) | Pass | View |
| Mar 2, 2026 | Tesamorelin | 98.14 % | 10.7 mg of 10 mg (7 %) | Pass | View |
What Inno Peptides sells
No current listings on record.
About Inno Peptides
Finnrick has tested 58 samples from Inno Peptides across 7 products.